626 related articles for article (PubMed ID: 9521507)
1. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ.
Gatalica Z
Pathol Res Pract; 1997; 193(11-12):753-8. PubMed ID: 9521507
[TBL] [Abstract][Full Text] [Related]
2. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
3. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers.
Leal C; Henrique R; Monteiro P; Lopes C; Bento MJ; De Sousa CP; Lopes P; Olson S; Silva MD; Page DL
Hum Pathol; 2001 May; 32(5):487-93. PubMed ID: 11381366
[TBL] [Abstract][Full Text] [Related]
4. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast.
Honma N; Takubo K; Akiyama F; Sawabe M; Arai T; Younes M; Kasumi F; Sakamoto G
Histopathology; 2005 Aug; 47(2):195-201. PubMed ID: 16045781
[TBL] [Abstract][Full Text] [Related]
5. Expression of androgen receptors and inhibin/activin alpha and betaA subunits in breast apocrine lesions.
Shim HS; Jung WH; Kim H; Park K; Cho NH
APMIS; 2006 May; 114(5):352-8. PubMed ID: 16725011
[TBL] [Abstract][Full Text] [Related]
6. Ductal carcinoma in situ of the breast: correlation between histologic classifications and biologic markers.
Moreno A; Lloveras B; Figueras A; Escobedo A; Ramon JM; Sierra A; Fabra A
Mod Pathol; 1997 Nov; 10(11):1088-92. PubMed ID: 9388058
[TBL] [Abstract][Full Text] [Related]
7. Apocrine metaplasia of breast cancer: clinicopathological features and predicting response.
Ogiya A; Horii R; Osako T; Ito Y; Iwase T; Eishi Y; Akiyama F
Breast Cancer; 2010 Oct; 17(4):290-7. PubMed ID: 19789945
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical localisation of androgen receptor in apocrine metaplasia and apocrine adenosis of the breast: relation to oestrogen and progesterone receptors.
Selim AG; Wells CA
J Clin Pathol; 1999 Nov; 52(11):838-41. PubMed ID: 10690175
[TBL] [Abstract][Full Text] [Related]
9. Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women.
Sapino A; Righi L; Cassoni P; Papotti M; Gugliotta P; Bussolati G
Mod Pathol; 2001 Aug; 14(8):768-76. PubMed ID: 11504836
[TBL] [Abstract][Full Text] [Related]
10. Cell turnover in apocrine metaplasia and apocrine adenosis of the breast.
Elayat G; Selim AG; Wells CA
Ann Diagn Pathol; 2010 Feb; 14(1):1-7. PubMed ID: 20123450
[TBL] [Abstract][Full Text] [Related]
11. Expression of c-erbB2, p53, Bcl-2, Bax, c-myc and Ki-67 in apocrine metaplasia and apocrine change within sclerosing adenosis of the breast.
Selim AG; El-Ayat G; Wells CA
Virchows Arch; 2002 Nov; 441(5):449-55. PubMed ID: 12447674
[TBL] [Abstract][Full Text] [Related]
12. Apocrine carcinomas of the breast in Turkish women: hormone receptors, c-erbB-2 and p53 immunoexpression.
Kaya H; Bozkurt SU; Erbarut I; Djamgoz MB
Pathol Res Pract; 2008; 204(6):367-71. PubMed ID: 18342452
[TBL] [Abstract][Full Text] [Related]
13. Coordinated expression of oestrogen and androgen receptors in HER2-positive breast carcinomas: impact on proliferative activity.
Lin Fde M; Pincerato KM; Bacchi CE; Baracat EC; Carvalho FM
J Clin Pathol; 2012 Jan; 65(1):64-8. PubMed ID: 22039288
[TBL] [Abstract][Full Text] [Related]
14. bcl-2 expression in the spectrum of preinvasive breast lesions.
Siziopikou KP; Prioleau JE; Harris JR; Schnitt SJ
Cancer; 1996 Feb; 77(3):499-506. PubMed ID: 8630957
[TBL] [Abstract][Full Text] [Related]
15. Molecular cytogenetic comparison of apocrine hyperplasia and apocrine carcinoma of the breast.
Jones C; Damiani S; Wells D; Chaggar R; Lakhani SR; Eusebi V
Am J Pathol; 2001 Jan; 158(1):207-14. PubMed ID: 11141494
[TBL] [Abstract][Full Text] [Related]
16. Clinical, histopathologic, and immunohistochemical features of microglandular adenosis and transition into in situ and invasive carcinoma.
Khalifeh IM; Albarracin C; Diaz LK; Symmans FW; Edgerton ME; Hwang RF; Sneige N
Am J Surg Pathol; 2008 Apr; 32(4):544-52. PubMed ID: 18300793
[TBL] [Abstract][Full Text] [Related]
17. Loss of heterozygosity is detected at chromosomes 1p35-36 (NB), 3p25 (VHL), 16p13 (TSC2/PKD1), and 17p13 (TP53) in microdissected apocrine carcinomas of the breast.
Lininger RA; Zhuang Z; Man Y; Park WS; Emmert-Buck M; Tavassoli FA
Mod Pathol; 1999 Dec; 12(12):1083-9. PubMed ID: 10619258
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical and molecular profiling of histologically defined apocrine carcinomas of the breast.
Vranic S; Marchiò C; Castellano I; Botta C; Scalzo MS; Bender RP; Payan-Gomez C; di Cantogno LV; Gugliotta P; Tondat F; di Celle PF; Mariani S; Gatalica Z; Sapino A
Hum Pathol; 2015 Sep; 46(9):1350-9. PubMed ID: 26208846
[TBL] [Abstract][Full Text] [Related]
19. Extramammary Paget disease is characterized by the consistent lack of estrogen and progesterone receptors but frequently expresses androgen receptor.
Diaz de Leon E; Carcangiu ML; Prieto VG; McCue PA; Burchette JL; To G; Norris BA; Kovatich AJ; Sanchez RL; Krigman HR; Gatalica Z
Am J Clin Pathol; 2000 Apr; 113(4):572-5. PubMed ID: 10761460
[TBL] [Abstract][Full Text] [Related]
20. Microsatellite alterations on human chromosome 11 in in situ and invasive breast cancer: a microdissection microsatellite analysis and correlation with p53, ER (estrogen receptor), and PR (progesterone receptor) protein immunoreactivity.
Shen KL; Yang LS; Hsieh HF; Chen CJ; Yu JC; Tsai NM; Harn HJ
J Surg Oncol; 2000 Jun; 74(2):100-7. PubMed ID: 10914818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
